Skip to main content
OpenTrials
Completed

NCT Number: NCT06189404

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

A phase 1, open-label, drug-drug interaction study to evaluate the effect of multiple doses of tigulixostat on the pharmacokinetics of single-dose theophylline in healthy adult volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, Ages 18 to 55, inclusive.
  • BMI 18.0 - 32.0 kg/m2, inclusive, at screening.
  • In good general health as determined by medical history, clinical laboratory assessments, vital sign measurements, 12-lead ECG results, and physical examination findings at screening.
  • Females of childbearing potential and males who agree to use contraception. Non-pregnant, non-lactating females who must have a negative pregnancy test at screening and check-in.

Exclusion criteria

  • Significant history or indications of ill-health, as judged by the investigator.
  • Any surgical or medical condition(s) possibly affecting drug absorption, distribution, metabolism, and excretion.
  • eGFRcr of <60 (mL/min)/1.73 m2 at screening.
  • alanine aminotransferase, aspartate aminotransferase, or total bilirubin ≥2 times the upper limit of normal at screening and check-in.
  • Used any prescription or over-the-counter medications (except acetaminophen [Tylenol] up to 2 g per day), including herbal or nutritional supplements, within 14 days before the first dose of study drug.
  • Consumed grapefruit or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or caffeine- or xanthine-containing products within 48 hours before the first dose of study drug.
  • History of hypersensitivity to theophylline or other xanthines and tigulixostat.

Treatment and study plan

Tigulixostat

Drug

300 mg oral dose

Other names: LC350189

Theophylline

Drug

400 mg oral dose

Primary outcomes

  1. AUC0-t of theophylline with and without tigulixostat

    Time frame: Up to 72 hours

  2. AUC0-inf of theophylline with and without tigulixostat

    Time frame: Up to 72 hours

  3. Cmax of theophylline with and without tigulixostat

    Time frame: Up to 72 hours

Secondary outcomes

  1. Incidence of reported adverse events (AEs)

    Time frame: Up to Day 28

  2. AUC0-t of tigulixostat and metabolite GD-MET-1

    Time frame: Up to 24 hours

  3. Cmax of tigulixostat and metabolite GD-MET-1

    Time frame: Up to 24 hours

Sponsors and collaborators

Lead sponsor

LG Chem

Industry

Registry information

Official study title

A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Oral Doses of Tigulixostat on the Pharmacokinetics of a Single Oral Dose of Theophylline

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jan 3, 2024
Registry last updated
Jan 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.